Robert Spraggins
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Instructor and Chief Resident
Also affiliated: Louisiana State University (2021); Louisiana State University in Shreveport (2021); University of Arkansas Medical Center (2025); Central Arkansas Veterans Healthcare System (2026)
Research Areas
Biography and Research Information
OverviewAI-generated summary
Robert Spraggins' research focuses on cardiovascular outcomes and related health conditions, with a significant portion of his recent work examining real-world data. He has investigated the association between cardiovascular outcomes in individuals undergoing percutaneous coronary intervention, with or without preceding coronary CT angiography. His publications also address the efficacy of various therapeutic interventions, including SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes and in obese non-diabetic patients with metabolic dysfunction-associated steatotic liver disease. Spraggins has also explored cardiovascular outcomes of GLP-1RA therapy in specific patient populations and the comparative effectiveness of different lipid-lowering therapies. His work includes reviews on AI-enhanced ECG for acute coronary syndrome triage and analyses of cardiovascular outcomes in relation to post-traumatic stress disorder. He has also contributed to understanding QRS fragmentation morphology and early repolarization during the COVID-19 pandemic.
Metrics
- h-index: 1
- Publications: 15
- Citations: 26
Positions
-
Instructor and Chief Resident publications 2023–2026University of Arkansas for Medical Sciences Institution web page
Selected Publications
-
AI-enhanced ECG for acute coronary syndrome triage: A state-of-the-art review (2026)
-
Examining the association between cardiovascular outcomes in individuals undergoing percutaneous coronary intervention with or without a preceding coronary CT angiogram (2026)
-
26-A-11242-ACC REAL-WORLD CARDIOVASCULAR OUTCOMES OF COMBINED SGLT2 INHIBITOR AND GLP1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES INDIVIDUALS (2026)
-
26-A-15959-ACC CARDIOVASCULAR OUTCOMES OF GLP-1RA THERAPY IN OBESE NON-DIABETIC PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: A REAL-WORLD ANALYSIS (2026)
-
1200.03 Real-World Cardiovascular Outcomes of Inclisiran Versus PCSK9 Monoclonal Antibodies Therapy in Individuals with Hyperlipidemia (2026)
-
Prevalence and Most Commonly Encountered QRS Fragmentation Morphology and Early Repolarization ST-Segment Changes During the Height of the COVID-19 Pandemic: A Single-Center Experience (2026)
-
HYPERTENSIVE RESPONSE DURING DOBUTAMINE STRESS ECHOCARDIOGRAPHY AND RISK OF NEW ONSET HEART FAILURE (2025)
-
SIGNIFICANCE OF ISCHEMIC ELECTROCARDIOGRAM CHANGES IN THE SETTING OF NORMAL IMAGING IN DOBUTAMINE STRESS ECHOCARDIOGRAPHY (2025)
-
Abstract 16061: Correlation Between Obesity and Ventricular Tachycardia in Individuals With HFrEF: Analysis From the DERIVATE Cohort (2023)
Collaboration Network
Top Collaborators
- Examining the association between cardiovascular outcomes in individuals undergoing percutaneous coronary intervention with or without a preceding coronary CT angiogram
- SIGNIFICANCE OF ISCHEMIC ELECTROCARDIOGRAM CHANGES IN THE SETTING OF NORMAL IMAGING IN DOBUTAMINE STRESS ECHOCARDIOGRAPHY
- HYPERTENSIVE RESPONSE DURING DOBUTAMINE STRESS ECHOCARDIOGRAPHY AND RISK OF NEW ONSET HEART FAILURE
- 26-A-15959-ACC CARDIOVASCULAR OUTCOMES OF GLP-1RA THERAPY IN OBESE NON-DIABETIC PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: A REAL-WORLD ANALYSIS
- 26-A-11242-ACC REAL-WORLD CARDIOVASCULAR OUTCOMES OF COMBINED SGLT2 INHIBITOR AND GLP1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES INDIVIDUALS
Showing 5 of 6 shared publications
- Examining the association between cardiovascular outcomes in individuals undergoing percutaneous coronary intervention with or without a preceding coronary CT angiogram
- 1200.03 Real-World Cardiovascular Outcomes of Inclisiran Versus PCSK9 Monoclonal Antibodies Therapy in Individuals with Hyperlipidemia
- 26-A-15959-ACC CARDIOVASCULAR OUTCOMES OF GLP-1RA THERAPY IN OBESE NON-DIABETIC PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: A REAL-WORLD ANALYSIS
- 26-A-11242-ACC REAL-WORLD CARDIOVASCULAR OUTCOMES OF COMBINED SGLT2 INHIBITOR AND GLP1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES INDIVIDUALS
- AI-enhanced ECG for acute coronary syndrome triage: A state-of-the-art review
- Abstract 16061: Correlation Between Obesity and Ventricular Tachycardia in Individuals With HFrEF: Analysis From the DERIVATE Cohort
- SIGNIFICANCE OF ISCHEMIC ELECTROCARDIOGRAM CHANGES IN THE SETTING OF NORMAL IMAGING IN DOBUTAMINE STRESS ECHOCARDIOGRAPHY
- HYPERTENSIVE RESPONSE DURING DOBUTAMINE STRESS ECHOCARDIOGRAPHY AND RISK OF NEW ONSET HEART FAILURE
- 26-A-11242-ACC REAL-WORLD CARDIOVASCULAR OUTCOMES OF COMBINED SGLT2 INHIBITOR AND GLP1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES INDIVIDUALS
- 1200.03 Real-World Cardiovascular Outcomes of Inclisiran Versus PCSK9 Monoclonal Antibodies Therapy in Individuals with Hyperlipidemia
- 26-A-15959-ACC CARDIOVASCULAR OUTCOMES OF GLP-1RA THERAPY IN OBESE NON-DIABETIC PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: A REAL-WORLD ANALYSIS
- 26-A-11242-ACC REAL-WORLD CARDIOVASCULAR OUTCOMES OF COMBINED SGLT2 INHIBITOR AND GLP1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES INDIVIDUALS
- AI-enhanced ECG for acute coronary syndrome triage: A state-of-the-art review
- Examining the association between cardiovascular outcomes in individuals undergoing percutaneous coronary intervention with or without a preceding coronary CT angiogram
- 1200.03 Real-World Cardiovascular Outcomes of Inclisiran Versus PCSK9 Monoclonal Antibodies Therapy in Individuals with Hyperlipidemia
- 26-A-15959-ACC CARDIOVASCULAR OUTCOMES OF GLP-1RA THERAPY IN OBESE NON-DIABETIC PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: A REAL-WORLD ANALYSIS
- 26-A-11242-ACC REAL-WORLD CARDIOVASCULAR OUTCOMES OF COMBINED SGLT2 INHIBITOR AND GLP1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES INDIVIDUALS
- Examining the association between cardiovascular outcomes in individuals undergoing percutaneous coronary intervention with or without a preceding coronary CT angiogram
- 26-A-15959-ACC CARDIOVASCULAR OUTCOMES OF GLP-1RA THERAPY IN OBESE NON-DIABETIC PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: A REAL-WORLD ANALYSIS
- 26-A-11242-ACC REAL-WORLD CARDIOVASCULAR OUTCOMES OF COMBINED SGLT2 INHIBITOR AND GLP1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES INDIVIDUALS
- SIGNIFICANCE OF ISCHEMIC ELECTROCARDIOGRAM CHANGES IN THE SETTING OF NORMAL IMAGING IN DOBUTAMINE STRESS ECHOCARDIOGRAPHY
- HYPERTENSIVE RESPONSE DURING DOBUTAMINE STRESS ECHOCARDIOGRAPHY AND RISK OF NEW ONSET HEART FAILURE
- SIGNIFICANCE OF ISCHEMIC ELECTROCARDIOGRAM CHANGES IN THE SETTING OF NORMAL IMAGING IN DOBUTAMINE STRESS ECHOCARDIOGRAPHY
- HYPERTENSIVE RESPONSE DURING DOBUTAMINE STRESS ECHOCARDIOGRAPHY AND RISK OF NEW ONSET HEART FAILURE
- SIGNIFICANCE OF ISCHEMIC ELECTROCARDIOGRAM CHANGES IN THE SETTING OF NORMAL IMAGING IN DOBUTAMINE STRESS ECHOCARDIOGRAPHY
- HYPERTENSIVE RESPONSE DURING DOBUTAMINE STRESS ECHOCARDIOGRAPHY AND RISK OF NEW ONSET HEART FAILURE
- SIGNIFICANCE OF ISCHEMIC ELECTROCARDIOGRAM CHANGES IN THE SETTING OF NORMAL IMAGING IN DOBUTAMINE STRESS ECHOCARDIOGRAPHY
- HYPERTENSIVE RESPONSE DURING DOBUTAMINE STRESS ECHOCARDIOGRAPHY AND RISK OF NEW ONSET HEART FAILURE
- SIGNIFICANCE OF ISCHEMIC ELECTROCARDIOGRAM CHANGES IN THE SETTING OF NORMAL IMAGING IN DOBUTAMINE STRESS ECHOCARDIOGRAPHY
- HYPERTENSIVE RESPONSE DURING DOBUTAMINE STRESS ECHOCARDIOGRAPHY AND RISK OF NEW ONSET HEART FAILURE
- SIGNIFICANCE OF ISCHEMIC ELECTROCARDIOGRAM CHANGES IN THE SETTING OF NORMAL IMAGING IN DOBUTAMINE STRESS ECHOCARDIOGRAPHY
- HYPERTENSIVE RESPONSE DURING DOBUTAMINE STRESS ECHOCARDIOGRAPHY AND RISK OF NEW ONSET HEART FAILURE
- SIGNIFICANCE OF ISCHEMIC ELECTROCARDIOGRAM CHANGES IN THE SETTING OF NORMAL IMAGING IN DOBUTAMINE STRESS ECHOCARDIOGRAPHY
- HYPERTENSIVE RESPONSE DURING DOBUTAMINE STRESS ECHOCARDIOGRAPHY AND RISK OF NEW ONSET HEART FAILURE
- SIGNIFICANCE OF ISCHEMIC ELECTROCARDIOGRAM CHANGES IN THE SETTING OF NORMAL IMAGING IN DOBUTAMINE STRESS ECHOCARDIOGRAPHY
- HYPERTENSIVE RESPONSE DURING DOBUTAMINE STRESS ECHOCARDIOGRAPHY AND RISK OF NEW ONSET HEART FAILURE
- Prevalence and Most Commonly Encountered QRS Fragmentation Morphology and Early Repolarization ST-Segment Changes During the Height of the COVID-19 Pandemic: A Single-Center Experience
- 26-A-11242-ACC REAL-WORLD CARDIOVASCULAR OUTCOMES OF COMBINED SGLT2 INHIBITOR AND GLP1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES INDIVIDUALS
Similar Researchers
Based on overlapping research topics